Imagine trying to find a needle in a haystack, but the needle looks different for every child. This project creates a specialized 'digital magnifying glass' and a 'scent detector' to spot skin cancer in young people much earlier. It uses AI to analyze images and breath patterns to catch the disease before it becomes dangerous.
Melanoma in young people is often misdiagnosed due to a lack of specialized guidelines and fragmented expertise. This leads to delayed treatment and poor patient outcomes.
A pan-European digital pathology workflow, AI-driven image analysis tools, and a non-invasive detection method based on breath and skin volatilomics.
If you are a diagnostic device manufacturer dealing with low accuracy in pediatric skin cancer screening — this project developed volatilomics detection from exhaled breath and skin that allows for earlier and more accurate prognosis.
If you are an AI Health-Tech startup dealing with a lack of specialized training data for young patients — this project developed image-based machine learning tools and a pan-European second-opinion platform specifically designed for CAYA melanoma.
If you are a private pathology laboratory dealing with fragmented expertise in rare pediatric cases — this project developed a digital pathology consultation workflow using HALO Link to enable scalable cross-border expert reviews.
Based on available project data, no specific pricing or cost structures for the developed tools have been disclosed.
The project is building a pan-European second-opinion platform and standardized digital pathology workflows, which suggests a design intended for cross-border scalability.
Based on available project data, specific patent or licensing agreements are not listed, though the results will be integrated into UNCAN.eu for re-usability.
The project uses interoperable datasets and REDCap codebooks to ensure data can be shared and integrated across different medical centers.
The project period runs from 2022-12-01 to 2026-11-30, indicating that final validated tools may be ready toward the end of 2026.
The consortium is heavily weighted toward research and academic expertise, featuring 10 research organizations and 9 universities. However, the inclusion of 2 industry partners and 1 SME, spanning 11 countries, provides a bridge for translating the 39 deliverables into commercial diagnostic tools.
Contact Fundacio de Recerca Clinica Barcelona-IIBB
Contact us to explore licensing opportunities for the volatilomics and AI diagnostic tools.
